Gene therapy for rheumatoid arthritis. Theoretical considerations
Current understanding of the pathogenesis of rheumatoid arthritis has provided evidence that therapeutic benefit can be achieved by using antagonists targeted to the inflammatory cytokines involved, mainly tumour necrosis factor-α and interleukin-1. Gene delivery of antagonists, which can inhibit th...
Guardado en:
| Autor principal: | |
|---|---|
| Publicado: |
1998
|
| Materias: | |
| Acceso en línea: | https://bibliotecadigital.exactas.uba.ar/collection/paper/document/paper_1170229X_v12_n1_p29_Chernajovsky http://hdl.handle.net/20.500.12110/paper_1170229X_v12_n1_p29_Chernajovsky |
| Aporte de: |
| id |
paper:paper_1170229X_v12_n1_p29_Chernajovsky |
|---|---|
| record_format |
dspace |
| spelling |
paper:paper_1170229X_v12_n1_p29_Chernajovsky2023-06-08T16:09:21Z Gene therapy for rheumatoid arthritis. Theoretical considerations Podhajcer, Osvaldo Luis antirheumatic agent antisense oligonucleotide cytokine cytokine receptor immunoglobulin enhancer binding protein immunoglobulin fragment interleukin 1 interleukin 1 receptor blocking agent interleukin 10 plasmid DNA transforming growth factor beta1 tumor necrosis factor alpha tumor necrosis factor alpha antibody virus vector cell type clinical trial complement system gene targeting gene therapy human major clinical study mediator meta analysis priority journal review rheumatoid arthritis Arthritis, Rheumatoid Gene Therapy Genetic Vectors Humans Current understanding of the pathogenesis of rheumatoid arthritis has provided evidence that therapeutic benefit can be achieved by using antagonists targeted to the inflammatory cytokines involved, mainly tumour necrosis factor-α and interleukin-1. Gene delivery of antagonists, which can inhibit the production or action of these cytokines and other mediators, has been achieved in experimental animal models. This new method of delivery can produce therapeutic effects at lower concentrations and in a local environment, overcoming the adverse effects that often accompany protein therapy. However, several technological and biological restraints preclude the immediate adaptation of this method to human treatment. Based on the experimental evidence, possible target therapeutic genes, cell types and vector systems that could be used are discussed in this article. Fil:Podhajcer, O.L. Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales; Argentina. 1998 https://bibliotecadigital.exactas.uba.ar/collection/paper/document/paper_1170229X_v12_n1_p29_Chernajovsky http://hdl.handle.net/20.500.12110/paper_1170229X_v12_n1_p29_Chernajovsky |
| institution |
Universidad de Buenos Aires |
| institution_str |
I-28 |
| repository_str |
R-134 |
| collection |
Biblioteca Digital - Facultad de Ciencias Exactas y Naturales (UBA) |
| topic |
antirheumatic agent antisense oligonucleotide cytokine cytokine receptor immunoglobulin enhancer binding protein immunoglobulin fragment interleukin 1 interleukin 1 receptor blocking agent interleukin 10 plasmid DNA transforming growth factor beta1 tumor necrosis factor alpha tumor necrosis factor alpha antibody virus vector cell type clinical trial complement system gene targeting gene therapy human major clinical study mediator meta analysis priority journal review rheumatoid arthritis Arthritis, Rheumatoid Gene Therapy Genetic Vectors Humans |
| spellingShingle |
antirheumatic agent antisense oligonucleotide cytokine cytokine receptor immunoglobulin enhancer binding protein immunoglobulin fragment interleukin 1 interleukin 1 receptor blocking agent interleukin 10 plasmid DNA transforming growth factor beta1 tumor necrosis factor alpha tumor necrosis factor alpha antibody virus vector cell type clinical trial complement system gene targeting gene therapy human major clinical study mediator meta analysis priority journal review rheumatoid arthritis Arthritis, Rheumatoid Gene Therapy Genetic Vectors Humans Podhajcer, Osvaldo Luis Gene therapy for rheumatoid arthritis. Theoretical considerations |
| topic_facet |
antirheumatic agent antisense oligonucleotide cytokine cytokine receptor immunoglobulin enhancer binding protein immunoglobulin fragment interleukin 1 interleukin 1 receptor blocking agent interleukin 10 plasmid DNA transforming growth factor beta1 tumor necrosis factor alpha tumor necrosis factor alpha antibody virus vector cell type clinical trial complement system gene targeting gene therapy human major clinical study mediator meta analysis priority journal review rheumatoid arthritis Arthritis, Rheumatoid Gene Therapy Genetic Vectors Humans |
| description |
Current understanding of the pathogenesis of rheumatoid arthritis has provided evidence that therapeutic benefit can be achieved by using antagonists targeted to the inflammatory cytokines involved, mainly tumour necrosis factor-α and interleukin-1. Gene delivery of antagonists, which can inhibit the production or action of these cytokines and other mediators, has been achieved in experimental animal models. This new method of delivery can produce therapeutic effects at lower concentrations and in a local environment, overcoming the adverse effects that often accompany protein therapy. However, several technological and biological restraints preclude the immediate adaptation of this method to human treatment. Based on the experimental evidence, possible target therapeutic genes, cell types and vector systems that could be used are discussed in this article. |
| author |
Podhajcer, Osvaldo Luis |
| author_facet |
Podhajcer, Osvaldo Luis |
| author_sort |
Podhajcer, Osvaldo Luis |
| title |
Gene therapy for rheumatoid arthritis. Theoretical considerations |
| title_short |
Gene therapy for rheumatoid arthritis. Theoretical considerations |
| title_full |
Gene therapy for rheumatoid arthritis. Theoretical considerations |
| title_fullStr |
Gene therapy for rheumatoid arthritis. Theoretical considerations |
| title_full_unstemmed |
Gene therapy for rheumatoid arthritis. Theoretical considerations |
| title_sort |
gene therapy for rheumatoid arthritis. theoretical considerations |
| publishDate |
1998 |
| url |
https://bibliotecadigital.exactas.uba.ar/collection/paper/document/paper_1170229X_v12_n1_p29_Chernajovsky http://hdl.handle.net/20.500.12110/paper_1170229X_v12_n1_p29_Chernajovsky |
| work_keys_str_mv |
AT podhajcerosvaldoluis genetherapyforrheumatoidarthritistheoreticalconsiderations |
| _version_ |
1768545612788137984 |